| Name | Title | Contact Details |
|---|---|---|
David Soper |
Director of Emerging Technology | Profile |
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.
Ltc Providers is a Sullivan, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Public Health Institute is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
H R Medical Supply is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.